Stay updated on Pembrolizumab and Olaparib in BRCA Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab and Olaparib in BRCA Breast Cancer Clinical Trial page.
Latest updates to the Pembrolizumab and Olaparib in BRCA Breast Cancer Clinical Trial page
- CheckyesterdayChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.1%
- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedThe website has been updated from version v2.14.0 to v2.14.1.SummaryDifference0.1%
- Check23 days agoChange DetectedThe type of intervention has been updated from version v2.13.3 to v2.14.0.SummaryDifference0.2%
- Check52 days agoChange DetectedThe study on Pembrolizumab in combination with Olaparib for advanced BRCA-mutated or HDR-defect breast cancer has transitioned from a recruiting status to 'active, not recruiting', with updated dates and a revision to version 2.13.3.SummaryDifference2%
- Check59 days agoChange DetectedThe website has updated the contact details section for the study, clarifying that it now provides information on who can answer questions about joining the study and where it is taking place, with a revision from v2.12.2 to v2.13.2.SummaryDifference2%
- Check74 days agoChange DetectedThe website has added a 'Show less' option, while several detailed data fields and download options related to study information have been removed.SummaryDifference3%
Stay in the know with updates to Pembrolizumab and Olaparib in BRCA Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and Olaparib in BRCA Breast Cancer Clinical Trial page.